Goldman Sachs’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2018
Q4 | – | Sell |
-70,113
| Closed | -$238K | – | 4379 |
|
2018
Q3 | $238K | Sell |
70,113
-50,425
| -42% | -$171K | ﹤0.01% | 3752 |
|
2018
Q2 | $453K | Sell |
120,538
-723,460
| -86% | -$2.72M | ﹤0.01% | 3568 |
|
2018
Q1 | $3.45M | Buy |
843,998
+154,575
| +22% | +$632K | ﹤0.01% | 2555 |
|
2017
Q4 | $3.21M | Sell |
689,423
-18,630
| -3% | -$86.6K | ﹤0.01% | 2555 |
|
2017
Q3 | $5.03M | Buy |
708,053
+22,380
| +3% | +$159K | ﹤0.01% | 2347 |
|
2017
Q2 | $4.96M | Buy |
685,673
+7,211
| +1% | +$52.1K | ﹤0.01% | 2286 |
|
2017
Q1 | $4.18M | Buy |
678,462
+22,388
| +3% | +$138K | ﹤0.01% | 2303 |
|
2016
Q4 | $3.85M | Buy |
656,074
+37,554
| +6% | +$220K | ﹤0.01% | 2334 |
|
2016
Q3 | $3.28M | Buy |
618,520
+186,758
| +43% | +$992K | ﹤0.01% | 2453 |
|
2016
Q2 | $2.86M | Buy |
431,762
+361,929
| +518% | +$2.4M | ﹤0.01% | 2422 |
|
2016
Q1 | $326K | Buy |
69,833
+3,362
| +5% | +$15.7K | ﹤0.01% | 3492 |
|
2015
Q4 | $336K | Sell |
66,471
-1,079,058
| -94% | -$5.45M | ﹤0.01% | 3459 |
|
2015
Q3 | $4.03M | Buy |
1,145,529
+1,027,323
| +869% | +$3.62M | ﹤0.01% | 2136 |
|
2015
Q2 | $1.18M | Buy |
118,206
+83,068
| +236% | +$829K | ﹤0.01% | 2867 |
|
2015
Q1 | $447K | Sell |
35,138
-29,647
| -46% | -$377K | ﹤0.01% | 3388 |
|
2014
Q4 | $917K | Sell |
64,785
-101,011
| -61% | -$1.43M | ﹤0.01% | 2986 |
|
2014
Q3 | $2.28M | Buy |
165,796
+2,201
| +1% | +$30.3K | ﹤0.01% | 2447 |
|
2014
Q2 | $2.52M | Buy |
163,595
+112,360
| +219% | +$1.73M | ﹤0.01% | 2405 |
|
2014
Q1 | $873K | Sell |
51,235
-514,373
| -91% | -$8.76M | ﹤0.01% | 3077 |
|
2013
Q4 | $7.33M | Sell |
565,608
-200,950
| -26% | -$2.6M | ﹤0.01% | 1742 |
|
2013
Q3 | $7.74M | Buy |
766,558
+231,868
| +43% | +$2.34M | ﹤0.01% | 1637 |
|
2013
Q2 | $3.99M | Buy |
+534,690
| New | +$3.99M | ﹤0.01% | 1899 |
|